scholarly journals Glycemic Excursion, Adverse Drug Reactions, and Self-Management in Diabetes Patients Undergoing Chemotherapy: A Literature Review

2021 ◽  
Vol 8 (6) ◽  
pp. 610
Author(s):  
Naoko Terao ◽  
Kumi Suzuki
Keyword(s):  
Literature Review ◽  
Adverse Drug Reactions ◽  
Self Management ◽  
Drug Reactions ◽  
Diabetes Patients

scholarly journals Analysis of Influence Factors of Quality of Life of Lung Cancer Patients with Skin Adverse Drug Reactions Under Targeted Therapy

2022 ◽  
Author(s):  
Ruofei Du ◽  
Xin Wang ◽  
Huiyue Zhou ◽  
Lixia Ma ◽  
Leon M. Larcher ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Targeted Therapy ◽  
Adverse Drug Reactions ◽  
Education Level ◽  
Self Management ◽  
Drug Reactions ◽  
The Status ◽  
Nsclc Patients

Abstract Purpose This study was to assess the status of quality of life and explore the possible factors correlated with quality of life among non-small cell lung cancer (NSCLC) patients with skin adverse drug reactions under targeted therapy. Methods We performed a cross-sectional study including 536 NSCLC patients with skin adverse drug reactions by targeted therapy in cancer outpatient clinics of three hospitals in China between May 2020 and May 2021. And we collected data with structured questionnaires and identified the relationships among coping style, self-management and quality of life by Pearson correlation analysis and multiple linear regression algorithm. Results The total score of quality of life was 46±12.84 in 536 NSCLC patients with skin adverse drug reactions undergoing targeted therapy. In multiple linear regression analysis, we identified the significant factors associated with quality of life including age, education level, combination of medicine, Charlson Comorbidity Index (CCI), stages of disease, facing, yield, symptom management, daily activity management, psychological and emotional management, self-efficacy and self-management (P < 0.05). Conclusions NSCLC patients with skin adverse drug reactions undergoing targeted therapy generally had a compromised quality of life. And the critical factors that affected the status of quality of life were age, education level, co-morbidity, the combinatorial application of drugs and stage of disease, self-management and coping styles.

scholarly journals THESIGNIFICANCE OF PHARMACOGENETIC TESTING FOR BETTER ANAESTHETIC OUTCOME AND LESSSURGICALSTRESS. Literature Review

2020 ◽  
Vol 10 (4) ◽  
pp. 112-117
Author(s):  
Kristina Tatzhikova ◽  
Bela Kantemirova ◽  
Aleksei Zhidovinov ◽  
Irakliy Kitiashvili
Keyword(s):  
Drug Interaction ◽  
Genetic Polymorphism ◽  
Literature Review ◽  
Adverse Drug Reactions ◽  
Genetic Screening ◽  
Web Of Science ◽  
Depth Of Anesthesia ◽  
Drug Reactions ◽  
Promising Tool ◽  
Stress Protection

The review is devoted to the problem of optimizing the anesthetic manual based on pharmacogenetic data in order to achieve an adequate depth of anesthesia and stress protection and reduce the number of adverse drug reactions. We analyzed the data of Pub Med and Web of Science databases to investigate the influence of genetic polymorphism on the body's response to the main groups of drugs used for anesthesia, and changes in the effects of drug interaction. Specifically, we have reported that the use of preoperative genetic screening for a set of markers (polymorphic alleles of a number of cytochromes) is a promising tool in the anesthesiologist's practice.

scholarly journals Avoiding adverse drug reactions by pharmacogenetic testing: A systematic review of the economic evidence in the case of TPMT and AZA-induced side effects

2008 ◽  
Vol 24 (03) ◽  
pp. 294-302 ◽  
Author(s):  
Amelia Compagni ◽  
Simona Bartoli ◽  
Bernhard Buehrlen ◽  
Giovanni Fattore ◽  
Dolores Ibarreta ◽  
...  
Keyword(s):  
Literature Review ◽  
Adverse Drug Reactions ◽  
Genetic Variants ◽  
Cost Data ◽  
Reliable Estimate ◽  
Cost Calculation ◽  
Small Scale ◽  
Economic Evidence ◽  
Drug Reactions ◽  
Pharmacogenetic Testing

Objectives:The study aims at evaluating the economic evidence related to testing for genetic variants of the drug-metabolizing enzyme, TPMT. Detecting TPMT genetic variants before the administration of azathioprine (AZA) has the potential to prevent serious and costly adverse drug reactions (ADRs), such as neutropenia. In particular, our analysis concentrated on assessing the reliability of data on costs of neutropenia and performing the tests, the two main cost categories that could inform an economic evaluation of TPMT pharmacogenetic testing.Methods:A systematic literature review was performed to gather evidence on the costs of testing and neutropenia. Articles were critically appraised for their comprehensiveness and quality. To better estimate costs of TPMT tests, a small-scale survey of European diagnostic laboratories was conducted.Results:Only seven articles were retrieved specifying the costs associated with the management and treatment of AZA-induced neutropenia. Most of these studies are based on theoretical modeling reconstructed with key-informants or on very few cases of ADRs, and either the methodology for cost calculation is not specified or costs are based on national cost databases and tariffs. After critical appraisal of these studies, we considered €2,116 as the most reliable estimate for the cost of a case of neutropenia. Literature review accompanied by the survey of several diagnostic laboratories also provided an estimate (€68) for TPMT testing. Based on these values, the net cost per prevented case of neutropenia equals to €5,300.Conclusions:Solid economic considerations related to TPMT pharmacogenetic testing are still limited by underreporting of ADRs and high level of approximation related to cost data. Ad hoc observational studies and the ADR recording process embedded in pharmacovigilance systems, established across Europe, should represent more reliable sources of cost data in the future.

Sign in / Sign up

Export Citation Format

Share Document